Peginterferon α in the treatment of chronic hepatitis B

Bibliography

• Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-70
   PubMed Web of Science ®Google Scholar
• Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003;46:400-7
   PubMed Web of Science ®Google Scholar
• Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92
   PubMed Web of Science ®Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Chen CL, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012;205:54-63
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012;206:1521-31
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51
   PubMed Web of Science ®Google Scholar
• Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304
   PubMed Web of Science ®Google Scholar
• Foser S, Schacher A, Weyer KA, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003;30:78-87
   PubMed Web of Science ®Google Scholar
• Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54:547-70
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-79. e1-4
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
   PubMed Web of Science ®Google Scholar
• Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-9
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013;62:290-8
   PubMed Web of Science ®Google Scholar
• Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007;1:415-30
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441-50
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-9. e3; quiz e13-4
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Chen CL, et al. Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers. J Infect Dis 2013;208:584-93
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-25. e2
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012;55:68-76
   PubMed Web of Science ®Google Scholar
• Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474-82
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327-34
   PubMed Web of Science ®Google Scholar
• Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43
   PubMed Web of Science ®Google Scholar
• Liu CJ, Lai MY, Chao YC, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006;43:742-9
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-9
   PubMed Web of Science ®Google Scholar
• Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705
   PubMed Web of Science ®Google Scholar
• Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002
   PubMed Web of Science ®Google Scholar
• Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13
   PubMed Web of Science ®Google Scholar
• Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44:541-8
   PubMed Web of Science ®Google Scholar
• Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011;16:629-37
   PubMed Web of Science ®Google Scholar
• Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34
   PubMed Web of Science ®Google Scholar
• Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62
   PubMed Web of Science ®Google Scholar
• Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716-25
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009;46:117-23
   PubMed Web of Science ®Google Scholar
• Yang HC, Chen CL, Shen YC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology 2013;57:934-43
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2012;56:67-75
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462-8
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
   PubMed Web of Science ®Google Scholar
• Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012;61(Suppl 1):i18-24
   PubMedGoogle Scholar
• Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology 2011;53:1054-5. author reply 1055
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872-80
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012;56:1006-11
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013;7:88-97
   PubMed Web of Science ®Google Scholar
• Su TH, Liu CJ, Yang HC, et al. Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. J Gastroenterol 2014;49(2):356-62
   PubMed Web of Science ®Google Scholar
• Jiang DK, Sun J, Cao G, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 2013;45:72-5
   PubMed Web of Science ®Google Scholar
• Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591-5
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:755-8
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513-20. e1
   PubMed Web of Science ®Google Scholar
• Wu X, Xin Z, Zhu X, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012;93:297-300
   PubMed Web of Science ®Google Scholar
• Holmes JA, Nguyen T, Ratnam D, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol 2013;28:861-6
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013;57:890-6
   PubMed Web of Science ®Google Scholar
• Wei L, Wedemeyer H, Liaw YF, et al. No association between IL28B genotype and response to peginterferon alfa-2a (40KD) in HBe antigen-positive and HBe antigen-negative patients with chronic hepatitis B from three large randomized clinical studies. Hepatology 2013;58:647A
   Web of Science ®Google Scholar
• Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 2011;53:422-8
   PubMed Web of Science ®Google Scholar
• An P, Winkler C, Guan L, et al. A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis 2011;203:943-7
   PubMed Web of Science ®Google Scholar
• Yan Z, Tan S, Dan Y, et al. Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections: case-control study and meta-analysis. Infect Genet Evol 2012;12:1222-8
   PubMed Web of Science ®Google Scholar
• Vermehren J, Lotsch J, Susser S, et al. A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers. PLoS ONE 2012;7:e32605
   PubMedGoogle Scholar
• Hu L, Zhai X, Liu J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012;55:1426-31
   PubMed Web of Science ®Google Scholar
• Cheng HR, Liu CJ, Tseng TC, et al. Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. PLoS One 2013;8:e53008
   PubMedGoogle Scholar
• Seto WK, Wong DK, Kopaniszen M, et al. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013;56:1695-703
   PubMed Web of Science ®Google Scholar
• Cheng L, Sun X, Tan S, et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in HBeAg seropositive chronic hepatitis B patients. Hepatol Res 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491-8
   PubMed Web of Science ®Google Scholar
• Liu CJ, Wang CC, Yang SS, et al. Entecavir plus pegylated interferon alfa-2a vs. entecavir alone in the treatment of HBeAg-positive chronic hepatitis B: an interim report. J Hepatol 2013;58:S308
   Google Scholar
• Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver Int 2014;Feb;34(Suppl 1):112-19
   PubMed Web of Science ®Google Scholar